First Time Loading...

Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 3.07 USD 3.37% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

ALLO Price Targets Summary
Allogene Therapeutics Inc

Wall Street analysts forecast ALLO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALLO is 9.88 USD with a low forecast of 4.44 USD and a high forecast of 17.85 USD.

ALLO Lowest Forecast
Wall Street Target
4.44 USD
45% Upside
ALLO Average Forecast
Wall Street Target
9.88 USD
222% Upside
ALLO Highest Forecast
Wall Street Target
17.85 USD
481% Upside
Lowest
Price Target
4.44 USD
45% Upside
Average
Price Target
9.88 USD
222% Upside
Highest
Price Target
17.85 USD
481% Upside
Allogene Therapeutics Inc Competitors:
Price Targets
A
ALVO
Alvotech SA
17% Upside
H
042520
Hans Biomed Corp
175% Upside
CRBU
Caribou Biosciences Inc
441% Upside
TLX
Telix Pharmaceuticals Ltd
2% Upside
A
ALVO
Alvotech SA
17% Upside
H
042520
Hans Biomed Corp
175% Upside
CRBU
Caribou Biosciences Inc
441% Upside
TLX
Telix Pharmaceuticals Ltd
2% Upside
KMDA
Kamada Ltd
113% Upside
4142
Adimmune Corp
27% Upside
DSGN
Design Therapeutics Inc
28% Upside
T
6628
Transcenta Holding Limited
364% Upside

Revenue
Forecast

Revenue Estimate
Allogene Therapeutics Inc

The compound annual growth rate of Allogene Therapeutics Inc's revenue for the next 3 years is 706%.

N/A
Past Growth
706%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Allogene Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Allogene Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-28%
Average Miss
What are analyst estimates?

See Also

Summary
ALLO intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALLO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALLO stock valuation using valuation multiples.
Wall Street Estimates
ALLO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALLO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALLO's stock price target?
Price Target
9.88 USD

According to Wall Street analysts, the average 1-year price target for ALLO is 9.88 USD with a low forecast of 4.44 USD and a high forecast of 17.85 USD.

What is Allogene Therapeutics Inc's Revenue forecast?
Projected CAGR
706%

The compound annual growth rate of Allogene Therapeutics Inc's revenue for the next 3 years is 706%.

ALPHA SPREAD
Join more than 134,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.